Login to Your Account


'Trk'-ish math: Loxo series B garners $24M for new cancer target

By Randy Osborne
Staff Writer

Wednesday, May 7, 2014

With $24 million of series B cash in hand, Loxo Oncology Inc. disclosed more about the pipeline's lead compound in a cancer effort than the company was willing when it garnered $33 million in the series A round last October.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription